The finding of a statistically significant association between Dupilumab use and progression/exacerbation of cutaneous T-cell lymphoma may sound surprising and contradict the literature, in that IL4 and IL13 are overexpressed in this malignancy and their dual suppression should inhibit the tumor. The gene discussed is IL13; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.